Anti-VEGF treatment is indicated for several retinal pathologies, mainly diabeticmacular edema (DME) that is caused by altered retinal vascular permeability, leadingto an increase in retinal thickness, formation of intraretinal cysts located mainlyin the plexiform layers (external and internal nuclear layers), and neovascularage-related macular degeneration (AMD), which is associated with neovascular macularmembrane formation with secondary exudation. The gene discussed is VEGFA; the disease is age-related macular degeneration.